Holen Sie sich die Stockscreener-App
0.9364
3.54%
0.032
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Technical Heatmap Flags Tevogen Bio Holdings Inc. Equity Warrant for Watch2025 Key Highlights & Expert-Curated Trade Recommendations - thegnnews.com
Tevogen Bio Holdings Inc. Stock Approaches Key Moving Average2025 Biggest Moves & Daily Profit Maximizing Trade Tips - newsyoung.net
Tevogen Bio's Strategic Financing and AI-Driven R&D Catalysts: A New Paradigm in Biopharma Innovation - AInvest
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 - GlobeNewswire
Tevogen Bio Holdings Inc. Enters into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts - MarketScreener
Tevogen Bio Holdings and the Path to Revenue by 2026: A Strategic Assessment of Risk, Innovation, and Capital Efficiency - AInvest
Tevogen Bio Holdings anticipates revenue by end of 2026 - MarketScreener
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum - The Manila Times
Tevogen Delivers Stronger Second Quarter and First Half - GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement - The Manila Times
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery - GlobeNewswire
RSI and MACD Indicate Shift in Tevogen Bio Holdings Inc. Equity Warrant SentimentJuly 2025 Weekly Recap & Free Community Consensus Stock Picks - classian.co.kr
Tevogen Bio Holdings Inc. Recovery Potential Based on Technical ToolsWeekly Trend Report & Low Risk Investment Opportunities - metal.it
Custom Dashboard Highlights Tevogen Bio Holdings Inc. Equity Warrant Price Momentum2025 Market Outlook & Stepwise Trade Signal Guides - 선데이타임즈
Why Tevogen Bio Holdings Inc. stock attracts strong analyst attentionJuly 2025 PostEarnings & Verified Entry Point Detection - sisaissue.com
Tevogen Bio Highlights Undervalued Intangible Assets, Citing Proprietary IP, AI Platforms And 74% Insider Ownership - 富途牛牛
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected - GlobeNewswire
RepeatTevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology - Investing News Network
Tevogen Bio Holdings Inc. Equity Warrant At Critical Juncture — Bounce or BreakdownJuly 2025 Big Picture & AI Forecast Swing Trade Picks - beatles.ru
Tevogen Receives $1M to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - AI Insider
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - MSN
Quant Strategy Flags Tevogen Bio Holdings Inc. Equity Warrant for EntrySwing Trading Plan With Smart Signals in Review - sundaytimes.kr
Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction - Benzinga
Tevogen Bio Holdings Inc. shares rise 1.53% premarket after reaffirming investor confidence and projecting $1 billion in oncology revenue. - AInvest
Tevogen Bio Oncology Reports Top-Line Revenue Forecast - GlobeNewswire
Tevogen Bio Holdings Inc. shares fall 1.53% premarket despite positive revenue forecasts and investor confidence. - AInvest
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line - GlobeNewswire
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion - GlobeNewswire
Biotech Unicorn Tevogen Bio Skyrockets from $4.2B to $10B Valuation: Inside the Massive Growth Story - Stock Titan
REPEATTevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders - GlobeNewswire
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion - The Manila Times
Tevogen Bio Projects Massive $22B Revenue From Revolutionary T Cell Therapies for Long COVID - Stock Titan
Tevogen Bio sees $1 bln revenue in launch year for oncology - MarketScreener
Biotech Revenue Breakthrough: Tevogen Bio Targets $14 Billion From Cancer and COVID Therapies - Stock Titan
Tevogen's Strategic AI and Biotech Convergence: Pioneering a New Era in Drug Development - AInvest
Tevogen Bio Holdings Expands into AI with Tevogen.AI - AInvest
Tevogen Bio Holdings Inc. Outlines Strategic Growth and Advancements in AI-Driven Healthcare Solutions - Quiver Quantitative
Tevogen's CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders. - AInvest
Beam Global to Release Q2 2025 Operating Results, Conference Call Scheduled for August 14, 2025 at 4:30 p.m. ET - The Globe and Mail
📈 Which tech stocks have recently seen an increase in institutional ownership? - AInvest
Tevogen's Explosive Institutional Investor Influx: A Signal of Biotech Breakout Potential - AInvest
Tevogen Bio Holdings Inc. shares rise 1.27% intraday after significant institutional ownership growth. - AInvest
Pinterest Q2 Earnings Miss Estimates Despite Y/Y Revenue Growth - The Globe and Mail
Tevogen Sees Significant Growth in Institutional Ownership - AInvest
5 Stocks to Buy on a Pullback - The Globe and Mail
Is Uber Still the Best Stock to Buy Now? - The Globe and Mail
P10 Holdings Reports Strong Q2 2025 Financial Results - The Globe and Mail
Targa Resources Announces $1 Billion Share Buyback - The Globe and Mail
What's Behind Marvell Technology Stock's Recent Surge? - The Globe and Mail
Tevogen sees 60% institutional ownership increase, led by Vanguard and BlackRock. - AInvest
Published on: 2025-08-08 09:01:56 - beatles.ru
NRG Energy Reports Strong Q2 2025 Results - The Globe and Mail
Iron Mountain Reports Record Earnings and Growth - The Globe and Mail
Twilio (TWLO) Q2 Revenue Jumps 13% - The Globe and Mail
Tevogen's AI-Driven Drug Discovery: A Strategic Inflection Point for Biotech Innovation - AInvest
Tevogen Bio: Revolutionizing Precision Medicine with AI-Driven Drug Discovery and Capital-Efficient Growth - AInvest
Tevogen Bio receives $1 mln grant for AI-driven drug discovery initiative. - AInvest
Tevogen Receives $1 Million to Accelerate AI-Driven Drug - GlobeNewswire
AI Drug Discovery Breakthrough: Tevogen Secures $10M Grant to Accelerate Cancer Treatment Innovation - Stock Titan
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):